Summary
Boston Scientific Corporation (BSX) filed an 8-K on August 9, 2002, primarily to disclose that its Chief Executive Officer and Chief Financial Officer submitted statements under oath to the SEC. These statements address facts and circumstances related to the company's past Exchange Act filings. The exact nature of these facts and circumstances, and the specific filings under scrutiny, are not detailed in this 8-K itself but are referenced as being attached as exhibits. This filing is significant for investors as it indicates potential issues or investigations concerning the accuracy and completeness of previous financial and corporate disclosures. While the 8-K doesn't provide specific details, the involvement of the CEO and CFO in sworn statements suggests a matter of considerable regulatory concern. Investors should closely examine the attached exhibits (99.1 and 99.2) for a deeper understanding of the issues, as these could have implications for the company's financial reporting, compliance, and stock valuation.
Key Highlights
- 1CEO and CFO submitted sworn statements to the SEC on August 9, 2002.
- 2Statements pertain to facts and circumstances regarding prior Exchange Act filings.
- 3The 8-K filing itself does not detail the specific issues or filings in question.
- 4Detailed information is expected to be found in attached Exhibits 99.1 and 99.2.
- 5This event signals potential regulatory scrutiny or past disclosure concerns.
- 6The filing is being made under Regulation FD Disclosure.